Chemotherapy in Treating Patients With Retinoblastoma

Status Completed

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with retinoblastoma.

Clinical Trial Description

OBJECTIVES: I. Estimate the response rate to adjuvant carboplatin (CBDCA) alone in children with intraocular retinoblastoma. II. Assess the overall survival, disease-free survival, and time to treatment failure in these patients. III. Attempt to maintain a 90% disease-free survival rate with this treatment. IV. Estimate the percentage of disease-free survivors who do not require the use of radiotherapy after adjuvant CBDCA. V. Assess the toxicity of this treatment. VI. Estimate the percentage of functional eyes salvaged using this radiation-sparing protocol and compare these results, in a nonrandomized manner, with historical treatment results in this population.

OUTLINE: Patients are stratified according to vitreous disease (yes vs no). Patients receive carboplatin IV over 1 hour on day 0. Treatment repeats every 2-3 weeks for 2 courses. Patients achieving complete response (CR) proceed to local control measures consisting of cryotherapy, laser photocoagulation, etc. (except brachytherapy). Patients not achieving CR continue with carboplatin until local control measures feasible. Patients with vitreous disease achieving CR receive 2 additional courses and then receive local control measures. Patients with vitreous disease not achieving CR receive intensive chemotherapy. Patients receive intensive chemotherapy consisting of vincristine IV on days 0, 7, and 14, cisplatin IV over 6 hours on day 0, etoposide IV on days 1 and 2, followed by cyclophosphamide IV over 60 minutes on days 1 and 2. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 3 and until blood counts recover. Treatment repeats every 2-4 weeks for 2 courses beyond CR. Patients are followed for 3 years.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study over 5-6 years. ;

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

Retinoblastoma

Clinical Trial Details

NCT number	NCT00002675
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Completed
Phase	Phase 2
Start date	May 1995
Completion date	January 2001

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04564521` - Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma.	N/A
Recruiting	`NCT02933333` - G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor	Phase 4
Withdrawn	`NCT01151748` - Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma	Phase 2
Completed	`NCT01048892` - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features	Phase 1
Active, not recruiting	`NCT00360750` - Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye	N/A
Completed	`NCT00003173` - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors	Phase 2
Enrolling by invitation	`NCT06227962` - Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
Completed	`NCT01661400` - Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors	Phase 1
Terminated	`NCT02617862` - PCI Imaging System in Pediatric Ophthalmology	N/A
Recruiting	`NCT02329002` - SPT Screening in Irradiated Hereditary Retinoblastoma Survivors	N/A
Terminated	`NCT01466855` - A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma	Early Phase 1
Completed	`NCT01505569` - Auto Transplant for High Risk or Relapsed Solid or CNS Tumors	N/A
Completed	`NCT00002515` - Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer	Phase 2
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Completed	`NCT06367569` - Evaluation of MRI of the Pineal Gland in Retinoblastoma
Completed	`NCT02193724` - Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma
Completed	`NCT01884194` - Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging	N/A
Terminated	`NCT01393769` - Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage	Phase 2
Completed	`NCT00006246` - Busulfan in Treating Children and Adolescents With Refractory CNS Cancer	Phase 1
Terminated	`NCT00003926` - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.